T-Cure Biosciences
Dr. Pantuck is the Chairman, Co-Founder, and Chief Medical Officer of Athos Therapeutics Inc. Prior to Athos, he was a Co-Founder of Kite Pharma, a leading cell therapy company that successfully developed and obtained FDA approval for innovative cancer immunotherapy and was acquired by Gilead Sciences in 2017. He is currently a Professor of Urology at UCLA David Geffen School of Medicine, Executive Chair of the UCLA IRB Committee, Vice-Chair of Academic Affairs for the Department of Urology, and a member of the Executive Committee of the Institute of Urologic Oncology. Dr. Pantuck serves on the scientific and advisory boards of several biotechnology and pharmaceutical companies. In addition to authoring several pending US patent applications, Dr. Pantuck has lectured internationally, written over 300 peer-reviewed biomedical publications, and consulted for major pharmaceutical and biotechnology companies providing his expertise on regulatory strategy and clinical trial design. He performed his urology/oncology fellowship and was awarded a Masters of Clinical Research from UCLA School of Medicine, and holds an MD degree from Robert Wood Johnson/Rutgers Medical School.
This person is not in the org chart
This person is not in any offices
T-Cure Biosciences
Founded by early pioneers of T cell receptor (TCR) therapy, T-Cure strives to find the cure for human cancer using its cutting-edge TCR-T technologies. Using its proprietary iSORT TCR discovery platform, T-Cure expects to rapidly grow its pipeline of therapy candidates. The Company believes its TCR holds great promise in treating patients unaddressed by current modalities.